{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:30:45Z","timestamp":1792002645971,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T00:00:00Z","timestamp":1385424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1038\/bjc.2013.742","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T21:03:29Z","timestamp":1385499809000},"page":"656-667","source":"Crossref","is-referenced-by-count":81,"title":["p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors"],"prefix":"10.1038","volume":"110","author":[{"given":"J","family":"Sonnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C D","family":"Palani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O H","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,26]]},"reference":[{"key":"BFbjc2013742_CR1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nm0796-811","volume":"2","author":"T Aas","year":"1996","unstructured":"Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811\u2013814.","journal-title":"Nat Med"},{"key":"BFbjc2013742_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nrd3674","volume":"11","author":"CH Arrowsmith","year":"2012","unstructured":"Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11: 384\u2013400.","journal-title":"Nat Rev Drug Discov"},{"key":"BFbjc2013742_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2637","volume":"7","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7: 1001\u20131012.","journal-title":"Nat Rev Drug Discov"},{"key":"BFbjc2013742_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11060-011-0791-2","volume":"107","author":"K Bajbouj","year":"2012","unstructured":"Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A, Schneider-Stock R (2012) P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol 107: 503\u2013516.","journal-title":"J Neurooncol"},{"key":"BFbjc2013742_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome\u2014biological and translational implications. Nat Rev Cancer 11: 726\u2013734.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2013742_CR6","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","volume":"15","author":"M Bots","year":"2009","unstructured":"Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15: 3970\u20133977.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013742_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nchembio.313","volume":"6","author":"JE Bradner","year":"2010","unstructured":"Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6: 238\u2013243.","journal-title":"Nat Chem Biol"},{"key":"BFbjc2013742_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jmcb\/mjs013","volume":"4","author":"A Brandl","year":"2012","unstructured":"Brandl A, Wagner T, Uhlig KM, Knauer SK, Stauber RH, Melchior F, Schneider G, Heinzel T, Kr\u00e4mer OH (2012) Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol 4: 284\u2013293.","journal-title":"J Mol Cell Biol"},{"key":"BFbjc2013742_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2009.02.028","volume":"280","author":"M Buchwald","year":"2009","unstructured":"Buchwald M, Kr\u00e4mer OH, Heinzel T (2009) HDACi\u2014targets beyond chromatin. Cancer Lett 280: 160\u2013167.","journal-title":"Cancer Lett"},{"key":"BFbjc2013742_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","volume":"282","author":"F Bunz","year":"1998","unstructured":"Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497\u20131501.","journal-title":"Science"},{"key":"BFbjc2013742_CR11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/onc.2010.566","volume":"30","author":"MM Chaturvedi","year":"2011","unstructured":"Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB (2011) NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615\u20131630.","journal-title":"Oncogene"},{"key":"BFbjc2013742_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrm1573","volume":"6","author":"JE Chipuk","year":"2005","unstructured":"Chipuk JE, Green DR (2005) Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 6: 268\u2013275.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFbjc2013742_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","volume":"153","author":"F Condorelli","year":"2008","unstructured":"Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL (2008) Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153: 657\u2013668.","journal-title":"Br J Pharmacol"},{"key":"BFbjc2013742_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1101\/gad.949602","volume":"16","author":"Y Deng","year":"2002","unstructured":"Deng Y, Lin Y, Wu X (2002) TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac\/DIABLO. Genes Dev 16: 33\u201345.","journal-title":"Genes Dev"},{"key":"BFbjc2013742_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-06-0541","volume":"6","author":"WX Ding","year":"2007","unstructured":"Ding WX, Ni HM, Chen X, Yu J, Zhang L, Yin XM (2007) A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther 6: 1062\u20131069.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2013742_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood-2008-10-182758","volume":"114","author":"L Ellis","year":"2009","unstructured":"Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114: 380\u2013393.","journal-title":"Blood"},{"key":"BFbjc2013742_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2011.02.019","volume":"306","author":"Y Fang","year":"2011","unstructured":"Fang Y, Nicholl MB (2011) Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett 306: 10\u201314.","journal-title":"Cancer Lett"},{"key":"BFbjc2013742_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7150\/ijbs.4283","volume":"8","author":"B Gu","year":"2012","unstructured":"Gu B, Zhu WG (2012) Surf the post-translational modification network of p53 regulation. Int J Biol Sci 8: 672\u2013684.","journal-title":"Int J Biol Sci"},{"key":"BFbjc2013742_CR19","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1038\/onc.2010.599","volume":"30","author":"S Hacker","year":"2011","unstructured":"Hacker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, Rutkowski S, Debatin KM, Fulda S (2011) Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 30: 2275\u20132281.","journal-title":"Oncogene"},{"key":"BFbjc2013742_CR20","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1074\/jbc.M213093200","volume":"278","author":"C Henderson","year":"2003","unstructured":"Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579\u201312589.","journal-title":"J Biol Chem"},{"key":"BFbjc2013742_CR21","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/sj.onc.1203963","volume":"19","author":"L Huang","year":"2000","unstructured":"Huang L, Sowa Y, Sakai T, Pardee AB (2000) Activation of the p21WAF1\/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712\u20135719.","journal-title":"Oncogene"},{"key":"BFbjc2013742_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm1160","volume":"11","author":"A Insinga","year":"2005","unstructured":"Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71\u201376.","journal-title":"Nat Med"},{"key":"BFbjc2013742_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ijc.20842","volume":"115","author":"J Joseph","year":"2005","unstructured":"Joseph J, Wajapeyee N, Somasundaram K (2005) Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. Int J Cancer 115: 11\u201318.","journal-title":"Int J Cancer"},{"key":"BFbjc2013742_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1158\/1078-0432.CCR-05-1230","volume":"12","author":"IA Kim","year":"2006","unstructured":"Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, Chie EK, Ha SW, Park CI, Kao GD (2006) Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 12: 940\u2013949.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013742_CR25","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","volume":"285","author":"PG Komarov","year":"1999","unstructured":"Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733\u20131737.","journal-title":"Science"},{"key":"BFbjc2013742_CR26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccr.2008.03.004","volume":"13","author":"S Lain","year":"2008","unstructured":"Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454\u2013463.","journal-title":"Cancer Cell"},{"key":"BFbjc2013742_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm0302-274","volume":"8","author":"H LeBlanc","year":"2002","unstructured":"LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A (2002) Tumor-cell resistance to death receptor\u2014induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274\u2013281.","journal-title":"Nat Med"},{"key":"BFbjc2013742_CR28","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1073\/pnas.0702294104","volume":"104","author":"RK Lindemann","year":"2007","unstructured":"Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104: 8071\u20138076.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2013742_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957\u2013967.","journal-title":"Cell"},{"key":"BFbjc2013742_CR30","first-page":"384","volume":"28","author":"J Meng","year":"2012","unstructured":"Meng J, Zhang HH, Zhou CX, Li C, Zhang F, Mei QB (2012) The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep 28: 384\u2013388.","journal-title":"Oncol Rep"},{"key":"BFbjc2013742_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/156800910791054149","volume":"10","author":"S M\u00fcller","year":"2010","unstructured":"M\u00fcller S, Kr\u00e4mer OH (2010) Inhibitors of HDACs\u2014effective drugs against cancer? Curr Cancer Drug Targets 10: 210\u2013228.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFbjc2013742_CR32","doi-asserted-by":"publisher","first-page":"19512","DOI":"10.1073\/pnas.0709443104","volume":"104","author":"M Nguyen","year":"2007","unstructured":"Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Sr. M, Goulet D, Viallet J, Belec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512\u201319517.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2013742_CR33","first-page":"4285","volume":"57","author":"PM O'Connor","year":"1997","unstructured":"O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285\u20134300.","journal-title":"Cancer Res"},{"key":"BFbjc2013742_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10637-010-9510-7","volume":"30","author":"CD Palani","year":"2012","unstructured":"Palani CD, Beck JF, Sonnemann J (2012) Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs 30: 25\u201336.","journal-title":"Invest New Drugs"},{"key":"BFbjc2013742_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ajpath.2010.11.010","volume":"178","author":"B Pandit","year":"2011","unstructured":"Pandit B, Gartel AL (2011) Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am J Pathol 178: 355\u2013360.","journal-title":"Am J Pathol"},{"key":"BFbjc2013742_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/38525","volume":"389","author":"K Polyak","year":"1997","unstructured":"Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389: 300\u2013305.","journal-title":"Nature"},{"key":"BFbjc2013742_CR37","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/nsmb.1872","volume":"17","author":"MV Poyurovsky","year":"2010","unstructured":"Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C (2010) The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982\u2013989.","journal-title":"Nat Struct Mol Biol"},{"issue":"13","key":"BFbjc2013742_CR38","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/onc.2013.120","volume":"33","author":"M Roth","year":"2013","unstructured":"Roth M, Chen WY (2013) Sorting out functions of sirtuins in cancer. Oncogene e-pub ahead of print 22 April 2013 doi:10.1038\/onc.2013.120.","journal-title":"Oncogene"},{"key":"BFbjc2013742_CR39","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1073\/pnas.191208598","volume":"98","author":"AA Ruefli","year":"2001","unstructured":"Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833\u201310838.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2013742_CR40","first-page":"90","volume":"1815","author":"G Schneider","year":"2011","unstructured":"Schneider G, Kr\u00e4mer OH (2011) NFkappaB\/p53 crosstalk-a promising new therapeutic target. Biochim Biophys Acta 1815: 90\u2013103.","journal-title":"Biochim Biophys Acta"},{"key":"BFbjc2013742_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.canlet.2005.02.009","volume":"232","author":"J Sonnemann","year":"2006","unstructured":"Sonnemann J, Hartwig M, Plath A, Saravana KK, M\u00fcller C, Beck JF (2006) Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett 232: 148\u2013160.","journal-title":"Cancer Lett"},{"key":"BFbjc2013742_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/35106009","volume":"1","author":"T Soussi","year":"2001","unstructured":"Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1: 233\u2013240.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2013742_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2011.267","volume":"31","author":"S Spiegel","year":"2012","unstructured":"Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537\u2013551.","journal-title":"Oncogene"},{"key":"BFbjc2013742_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137: 413\u2013431.","journal-title":"Cell"},{"key":"BFbjc2013742_CR45","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1038\/sj.onc.1203176","volume":"18","author":"JA Vrana","year":"1999","unstructured":"Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2\/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016\u20137025.","journal-title":"Oncogene"},{"key":"BFbjc2013742_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83\u201396.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2013742_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/jnci\/94.7.504","volume":"94","author":"X Yu","year":"2002","unstructured":"Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504\u2013513.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2013742_CR48","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1128\/MCB.26.7.2782-2790.2006","volume":"26","author":"Y Zhao","year":"2006","unstructured":"Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG (2006) Acetylation of p53 at lysine 373\/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1\/Cip1). Mol Cell Biol 26: 2782\u20132790.","journal-title":"Mol Cell Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2013742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013742","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2013742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:20:31Z","timestamp":1684416031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,26]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["BFbjc2013742"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.742","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,26]]}}}